Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Acute Urinary Retention, Benign Prostatic Hyperplasia, Benign Prostatic Obstruction

In brief

Acute urinary retention is a common emergency in men with benign prostatic hyperplasia. After bladder drainage with a urethral catheter, patients usually undergo a trial without catheter to determine whether they can pass urine again without recatheterization. This study will evaluate whether adding tadalafil 5 mg once daily to tamsulosin 0.4 mg once daily improves the chance of successful trial without catheter in men with first-episode acute urinary retention due to presumed benign prostatic hyperplasia. Participants will be randomly assigned to receive either tamsulosin plus tadalafil or tamsulosin plus a matching placebo. Study medication will start within 24 hours after catheterization. The catheter will be removed on Day 7. If the first trial without catheter fails, the catheter will be reinserted and a second rescue trial without catheter will be performed on Day 14. The main outcome is overall catheter-free success by Day 14. Participants will also be followed for recurrent urinary retention, post-void residual urine, urinary flow, catheter-related complications, drug-related adverse events, and the need for benign prostatic hyperplasia-related surgery within 3 months.

Key facts

Study ID

NCT07654413

Run by

Beni-Suef University

People needed

320

Starts

2026-06-08

Expected to finish

2027-12-01

Last updated by the study team

2026-06-17

Who can join

Age: 50 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male patient aged 50 years or older.
• First episode of spontaneous painful acute urinary retention.
• Successful urethral catheterization at presentation.
• Drained urine volume at presentation of at least 300 mL.
• Clinical impression of benign prostatic obstruction or benign prostatic hyperplasia based on history, digital rectal examination, and/or ultrasound evidence of enlarged prostate.
• Ability to provide written informed consent.

You may not qualify if…

• Previous episode of acute urinary retention.
• Chronic painless urinary retention phenotype.
• Active urinary tract infection or sepsis.
• Gross hematuria with clot retention.
• Suspected or known urethral stricture.
• Neurogenic bladder or major neurologic disease affecting voiding.
• History of prostate cancer or bladder cancer.
• Previous prostate surgery.
• Current use of nitrates or guanylate cyclase stimulators.
• Contraindication to tadalafil or tamsulosin.
• Severe hypotension or unstable cardiovascular disease.
• Severe renal impairment.
• Severe hepatic impairment.
• Current or recent use of phosphodiesterase type 5 inhibitors before enrollment.

Where it is running

• Department of Urology- Beni-Suef University Hospitals — Banī Suwayf, Beni Suweif Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.